The majority of ovarian cancers are diagnosed at advanced stages, and there are furthermore few therapeutic options for ovarian cancer patients. Though in-vitro knockout studies, and in-vivo expression level studies a research group led by Dr Benjamin Bitler have identified CBX2 as a important driver in ovarian cancer progression. The researchers aim to target CBX2 as a novel treatment for ovarian cancer to provide a treatment option to advanced stage ovarian cancer patients.